Scholarlink

Background <p>The present study aims to evaluate regulatory frameworks in tackling anti-microbial resistance (AMR) across the US &amp; Europe. It examines the WHO’s Global Action Plan (GAP) on AMR, legislation, clinical trials, and various strategies to combat the rising threat of AMR with a focus on Qualified Infectious Disease Product (QIDP) and PRIME designation approvals.</p> Objective <p>This study analyzes regulatory policies, legislation in the US &amp; Europe, and various strategies addressing AMR globally, and provides recommendations to enhance and streamline them, ultimately combating the AMR crisis.</p> Methods <p>Data on regulatory policies were sourced from authoritative entities like the FDA (US) and EMA (EU), EU commission. The study also examined national action plans (NAPs) for AMR in these regions and the WHO’s GAP. Information on drug products approved for AMR under the Generating Antibiotic Incentives Now (GAIN) Act was obtained from the US FDA and PRIME designation of EMA, while incentives for tackling AMR were assessed from various legal sites in both countries.</p> Results <p>The study reveals a complex regulatory landscape, with varying degrees of implementation and adherence across the US &amp; EU. The WHO’s GAP highlights the need for a unified global approach. The US has initiatives like the GAIN Act. The 24 QIDP-designated drugs approved by the FDA demonstrate the US’s focus on tackling AMR. Alternative strategies show promise but require further research to ensure efficacy and safety. EMA demonstrated a proactive and flexible approach to combating antimicrobial resistance through initiatives like PRIME designation and Stewardship and Access Plans.</p> Conclusion <p>AMR is a critical global health issue requiring immediate and coordinated action. Strengthening regulatory frameworks, enforcing legislation, and promoting responsible antimicrobial use are essential. Investment in new treatments and global collaboration is crucial to combat AMR effectively.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Delving into the Regulations, Policies, Legislation, and Diversified Strategies across the US & Europe for Tackling Antimicrobial Resistance

  • 期刊论文

  • 发表日期：

    2026年3月13日

查看全文
  • Pooja Shende,
  • Ramesh Joga,
  • Sravani Yerram,
  • Kajal Gandhi,
  • M. Sowndharya,
  • Saurabh Srivastava

摘要

Background

The present study aims to evaluate regulatory frameworks in tackling anti-microbial resistance (AMR) across the US & Europe. It examines the WHO’s Global Action Plan (GAP) on AMR, legislation, clinical trials, and various strategies to combat the rising threat of AMR with a focus on Qualified Infectious Disease Product (QIDP) and PRIME designation approvals.

Objective

This study analyzes regulatory policies, legislation in the US & Europe, and various strategies addressing AMR globally, and provides recommendations to enhance and streamline them, ultimately combating the AMR crisis.

Methods

Data on regulatory policies were sourced from authoritative entities like the FDA (US) and EMA (EU), EU commission. The study also examined national action plans (NAPs) for AMR in these regions and the WHO’s GAP. Information on drug products approved for AMR under the Generating Antibiotic Incentives Now (GAIN) Act was obtained from the US FDA and PRIME designation of EMA, while incentives for tackling AMR were assessed from various legal sites in both countries.

Results

The study reveals a complex regulatory landscape, with varying degrees of implementation and adherence across the US & EU. The WHO’s GAP highlights the need for a unified global approach. The US has initiatives like the GAIN Act. The 24 QIDP-designated drugs approved by the FDA demonstrate the US’s focus on tackling AMR. Alternative strategies show promise but require further research to ensure efficacy and safety. EMA demonstrated a proactive and flexible approach to combating antimicrobial resistance through initiatives like PRIME designation and Stewardship and Access Plans.

Conclusion

AMR is a critical global health issue requiring immediate and coordinated action. Strengthening regulatory frameworks, enforcing legislation, and promoting responsible antimicrobial use are essential. Investment in new treatments and global collaboration is crucial to combat AMR effectively.